Amgen (AMGN) and AstraZeneca (AZN) announced that the U.S. FDA approved Tezspire for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps in adult and pediatric patients aged 12 years and older. Tezspire is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Merck KGaA Joins Price Cut Agreement with Trump to Dodge Tariffs
- Amgen treatment of systemic sclerosis granted FDA orphan designation
- What’s Included in AstraZeneca’s (AZN) ‘Historic’ Drug Discount Deal with Trump?
- AstraZeneca Stock (AZN) Flat despite Incoming Trump Pricing Deal, Virginia Plant Construction
- Trump Weekly: Generics to be excluded from pharma tariff plan